Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Journal
Affiliation country
Publication year range
1.
Cell ; 170(2): 352-366.e13, 2017 Jul 13.
Article in English | MEDLINE | ID: mdl-28709002

ABSTRACT

Interactions between stromal fibroblasts and cancer cells generate signals for cancer progression, therapy resistance, and inflammatory responses. Although endogenous RNAs acting as damage-associated molecular patterns (DAMPs) for pattern recognition receptors (PRRs) may represent one such signal, these RNAs must remain unrecognized under non-pathological conditions. We show that triggering of stromal NOTCH-MYC by breast cancer cells results in a POL3-driven increase in RN7SL1, an endogenous RNA normally shielded by RNA binding proteins SRP9/14. This increase in RN7SL1 alters its stoichiometry with SRP9/14 and generates unshielded RN7SL1 in stromal exosomes. After exosome transfer to immune cells, unshielded RN7SL1 drives an inflammatory response. Upon transfer to breast cancer cells, unshielded RN7SL1 activates the PRR RIG-I to enhance tumor growth, metastasis, and therapy resistance. Corroborated by evidence from patient tumors and blood, these results demonstrate that regulation of RNA unshielding couples stromal activation with deployment of RNA DAMPs that promote aggressive features of cancer. VIDEO ABSTRACT.


Subject(s)
Breast Neoplasms/pathology , Exosomes/pathology , RNA, Untranslated/metabolism , Stromal Cells/pathology , Tumor Microenvironment , Breast Neoplasms/metabolism , DEAD Box Protein 58/metabolism , Exosomes/metabolism , Humans , Interferon Regulatory Factors/metabolism , MCF-7 Cells , Neoplasm Metastasis , RNA Polymerase III/genetics , RNA Polymerase III/metabolism , Receptors, Immunologic , Receptors, Pattern Recognition/metabolism , Signal Recognition Particle/metabolism , Stromal Cells/metabolism , Virus Diseases/metabolism
2.
Cell ; 167(6): 1540-1554.e12, 2016 Dec 01.
Article in English | MEDLINE | ID: mdl-27912061

ABSTRACT

Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.


Subject(s)
CTLA-4 Antigen/antagonists & inhibitors , Melanoma/immunology , Melanoma/therapy , Radioimmunotherapy , Animals , B7-H1 Antigen/metabolism , Cell Line, Tumor , Drug Resistance, Neoplasm , Heterografts , Humans , Interferons/immunology , Melanoma/drug therapy , Melanoma/radiotherapy , Mice , Neoplasm Transplantation , STAT1 Transcription Factor , T-Lymphocytes/immunology
3.
Cell ; 159(3): 499-513, 2014 Oct 23.
Article in English | MEDLINE | ID: mdl-25417103

ABSTRACT

Stromal communication with cancer cells can influence treatment response. We show that stromal and breast cancer (BrCa) cells utilize paracrine and juxtacrine signaling to drive chemotherapy and radiation resistance. Upon heterotypic interaction, exosomes are transferred from stromal to BrCa cells. RNA within exosomes, which are largely noncoding transcripts and transposable elements, stimulates the pattern recognition receptor RIG-I to activate STAT1-dependent antiviral signaling. In parallel, stromal cells also activate NOTCH3 on BrCa cells. The paracrine antiviral and juxtacrine NOTCH3 pathways converge as STAT1 facilitates transcriptional responses to NOTCH3 and expands therapy-resistant tumor-initiating cells. Primary human and/or mouse BrCa analysis support the role of antiviral/NOTCH3 pathways in NOTCH signaling and stroma-mediated resistance, which is abrogated by combination therapy with gamma secretase inhibitors. Thus, stromal cells orchestrate an intricate crosstalk with BrCa cells by utilizing exosomes to instigate antiviral signaling. This expands BrCa subpopulations adept at resisting therapy and reinitiating tumor growth.


Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Exosomes/metabolism , Paracrine Communication , Stromal Cells/metabolism , Animals , Breast Neoplasms/metabolism , Cell Line, Tumor , Computer Simulation , Drug Resistance, Neoplasm , Female , Humans , Interferons/metabolism , Mice, Nude , Radiation Tolerance , Receptors, Notch/metabolism , STAT1 Transcription Factor/metabolism , Signal Transduction , rab GTP-Binding Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL